BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 20843377)

  • 1. Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402.
    Baba T; Sato-Matsushita M; Kanamoto A; Itoh A; Oyaizu N; Inoue Y; Kawakami Y; Tahara H
    J Transl Med; 2010 Sep; 8():84. PubMed ID: 20843377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
    Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
    Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients.
    Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Teates D; Neese P; Grosh WW; Petroni G; Engelhard VH; Slingluff CL
    Int J Cancer; 2001 Jun; 92(5):703-11. PubMed ID: 11340576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination.
    Vence LM; Wang C; Pappu H; Anson RE; Patel TA; Miller P; Bassett R; Lizee G; Overwijk WW; Komanduri K; Benjamin C; Alvarado G; Patel SP; Kim K; Papadopoulos NE; Bedikian AY; Homsi J; Hwu WJ; Boyd R; Radvanyi L; Hwu P
    J Immunother; 2013 May; 36(4):276-86. PubMed ID: 23603862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination.
    Voelkl S; Moore TV; Rehli M; Nishimura MI; Mackensen A; Fischer K
    Cancer Immunol Immunother; 2009 May; 58(5):709-18. PubMed ID: 18836718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients.
    Zajac P; Oertli D; Marti W; Adamina M; Bolli M; Guller U; Noppen C; Padovan E; Schultz-Thater E; Heberer M; Spagnoli G
    Hum Gene Ther; 2003 Nov; 14(16):1497-510. PubMed ID: 14577912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells.
    Kawashima I; Tsai V; Southwood S; Takesako K; Celis E; Sette A
    Int J Cancer; 1998 Nov; 78(4):518-24. PubMed ID: 9797143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma.
    Pullarkat V; Lee PP; Scotland R; Rubio V; Groshen S; Gee C; Lau R; Snively J; Sian S; Woulfe SL; Wolfe RA; Weber JS
    Clin Cancer Res; 2003 Apr; 9(4):1301-12. PubMed ID: 12684398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.
    Slingluff CL; Yamshchikov G; Neese P; Galavotti H; Eastham S; Engelhard VH; Kittlesen D; Deacon D; Hibbitts S; Grosh WW; Petroni G; Cohen R; Wiernasz C; Patterson JW; Conway BP; Ross WG
    Clin Cancer Res; 2001 Oct; 7(10):3012-24. PubMed ID: 11595689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination.
    Powell DJ; Rosenberg SA
    J Immunother; 2004; 27(1):36-47. PubMed ID: 14676632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patients.
    Castelli C; Mazzocchi A; Rini F; Tarsini P; Rivoltini L; Maio M; Gallino G; Belli F; Parmiani G
    Eur J Immunol; 1998 Apr; 28(4):1143-54. PubMed ID: 9565353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens.
    Phan GQ; Touloukian CE; Yang JC; Restifo NP; Sherry RM; Hwu P; Topalian SL; Schwartzentruber DJ; Seipp CA; Freezer LJ; Morton KE; Mavroukakis SA; White DE; Rosenberg SA
    J Immunother; 2003; 26(4):349-56. PubMed ID: 12843797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
    Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
    Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used.
    Lesterhuis WJ; Schreibelt G; Scharenborg NM; Brouwer HM; Gerritsen MJ; Croockewit S; Coulie PG; Torensma R; Adema GJ; Figdor CG; de Vries IJ; Punt CJ
    Cancer Immunol Immunother; 2011 Feb; 60(2):249-60. PubMed ID: 21069321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes.
    Robbins PF; El-Gamil M; Li YF; Fitzgerald EB; Kawakami Y; Rosenberg SA
    J Immunol; 1997 Jul; 159(1):303-8. PubMed ID: 9200467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail.
    Akiyama Y; Maruyama K; Nara N; Mochizuki T; Yamamoto A; Yamazaki N; Kawashima I; Nukaya I; Takesako K; Yamaguchi K
    Anticancer Res; 2004; 24(2B):571-7. PubMed ID: 15160996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
    Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
    Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines.
    Asai T; Storkus WJ; Whiteside TL
    Clin Diagn Lab Immunol; 2000 Mar; 7(2):145-54. PubMed ID: 10702485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.